Vis enkel innførsel

dc.contributor.authorFløtten, Øystein
dc.contributor.authorGrønberg, Bjørn Henning
dc.contributor.authorBremnes, Roy M.
dc.contributor.authorAmundsen, Tore
dc.contributor.authorSundstrøm, Stein Harald
dc.contributor.authorRolke, Heidi
dc.contributor.authorHORNSLIEN, KJERSTI
dc.contributor.authorWentzel-Larsen, Tore
dc.contributor.authorAasebø, Ulf
dc.contributor.authorvon Plessen, Christian
dc.date.accessioned2022-05-31T09:34:57Z
dc.date.available2022-05-31T09:34:57Z
dc.date.issued2012-07-03
dc.description.abstractBACKGROUND: Platinum-based doublet chemotherapy is the standard first-line treatment for advanced non-small cell lung cancer (NSCLC), but earlier studies have suggested that non-platinum combinations are equally effective and better tolerated. We conducted a national, randomised study to compare a non-platinum with a platinum combination.<p> <p>METHODS: Eligible patients had stage IIIB/IV NSCLC and performance status (PS) 0-2. Patients received up to three cycles of vinorelbine 60 mg m <sup>-2</sup> p.o. þ gemcitabine 1000 mg m <sup>-2</sup> i.v. day 1 and 8 (VG) or vinorelbine 60 mg m<sup>-2</sup> p.o. day 1 and 8 þ carboplatin area under the curve ¼ 5 (Calvert’s formula) i.v. day 1 (VC). Patients X75 years received 75% of the dose. Endpoints were overall survival, health-related quality of life (HRQoL), toxicity, and the use of radiotherapy. <p>RESULTS: We randomised 444 patients from September 2007 to April 2009. The median age was 65 years, 58% were men and 25% had PS 2. Median survival was VG: 6.3 months; VC: 7.0 months, P ¼ 0.802. Vinorelbine plus carboplatin patients had more grade III/IV nausea/vomiting (VG: 4%, VC: 12%, P ¼ 0.008) and grade IV neutropenia (VG: 7%, VC: 19%, Po0.001). Infections, HRQoL and the use of radiotherapy did not differ significantly between the treatment groups. <p>CONCLUSION: The two regimens yielded similar overall survival. The VG combination had only a slightly better toxicity profile.en_US
dc.identifier.citationFløtten Ø, Grønberg BH, Bremnes RM, Amundsen T, Sundstrøm SH, Rolke H, HORNSLIEN K, Wentzel-Larsen T, Aasebø U, von Plessen C. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. British Journal of Cancer. 2012;107(3):442-447en_US
dc.identifier.cristinIDFRIDAID 963632
dc.identifier.doi10.1038/bjc.2012.284
dc.identifier.issn0007-0920
dc.identifier.issn1532-1827
dc.identifier.urihttps://hdl.handle.net/10037/25325
dc.language.isoengen_US
dc.publisherSpringer Natureen_US
dc.relation.journalBritish Journal of Cancer
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2012 The Author(s)en_US
dc.subjectVDP::Medisinske fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Klinisk farmakologi: 739en_US
dc.subjectVDP::Midical sciences: 700::Basic medical, dental and veterinary sciences: 710::Clinical pharmacology: 739en_US
dc.subjectVDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.subjectVDP::Midical sciences: 700::Clinical medical sciences: 750::Oncology: 762en_US
dc.titleVinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Groupen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel